Ang1005
From PeptidePlaza, the free peptide reference · Entry #1050 · Nootropic · Sources fetched 2026-09-10 · Editorial standards
Ang1005 (also known as paclitaxel trevatida, Paclitaxel trevatide, paclitaxelum trevatidum) is a nootropic research peptide. Ang1005, also known as paclitaxel trevatide, is a prolow-density lipoprotein receptor-related protein 1 binding agent and tubulin inhibitor.
Ang1005 is a peptide-drug conjugate that functions as a prolow-density lipoprotein receptor-related protein 1 binding agent and a tubulin inhibitor. It is designed to cross the blood-brain barrier and has shown activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Ang1005 is currently in Phase 3 clinical trials and has been studied for indications such as glioblastoma, brain neoplasms, paraganglioma, neoplasms, and glioma. Research has explored its antitumour activity and the influence of the glioma tumour microenvironment on its transport.
1 Mechanism of action
Prolow-density lipoprotein receptor-related protein 1 binding agent (binding agent); Tubulin inhibitor (inhibitor)
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Glioblastoma
- Brain Neoplasms
- Paraganglioma
- Neoplasms
- Glioma
3 Chemical and physical properties
| CAS number | 1075214-55-9 |
|---|---|
| Molar mass | 5109 g/mol |
| Purity (typical) | Not independently verified |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
4 Research studies (8)
- ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Clinical cancer research : an official journal of the American Association for Cancer Research (2020) - Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)
Genes & diseases (2017) - Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1
British journal of cancer (2011) - Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2
British journal of pharmacology (2008) - Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer
Seminars in cancer biology (2021) · Review - Current challenges in the management of breast cancer brain metastases
Seminars in oncology (2017) · Review - Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer
Pharmaceutical research (2009) - Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles
Drug design, development and therapy (2026) · Review
5 Safety and risk profile
5.1 Regulatory status
Ang1005 is currently classified as Phase 3 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is Ang1005?
- Ang1005, also known as paclitaxel trevatide, is a peptide-drug conjugate. It acts as a prolow-density lipoprotein receptor-related protein 1 binding agent and a tubulin inhibitor, designed to target and inhibit cancer cell growth.
- How does Ang1005 work?
- Ang1005 works by binding to prolow-density lipoprotein receptor-related protein 1 and inhibiting tubulin. This dual mechanism allows it to interfere with cellular processes essential for cancer cell proliferation, and it is designed to cross the blood-brain barrier.
- What is Ang1005 studied for?
- Ang1005 is studied for various types of cancer, including glioblastoma, brain neoplasms, paraganglioma, neoplasms, and glioma. It has shown activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.
- What is the regulatory status of Ang1005?
- Ang1005 is currently in Phase 3 clinical trials. It has reached Phase 2 for glioblastoma, brain neoplasms, and paraganglioma, and Phase 1 for neoplasms and glioma.
7 References
- Ang1005 — compound summary PubChem. View source
- Ang1005 — molecule record ChEMBL. View source
- Ang1005 — published literature (14 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Ang1005.
Also nootropic
Davunetide, also known as NAP peptide, is a tubulin stabiliser studied for its potential in neurological disorders.
Also nootropic
Substance P, also known as Neurokinin P, is an endogenous human peptide and a member of the tachykinin family.
Also nootropic
Vasoactive Intestinal Peptide (VIP) is a neuropeptide that activates VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2), which are G protein-coupled receptors.
Also nootropic
A nine-amino-acid neuropeptide hormone best known for childbirth and lactation, now studied extensively for social bonding, stress regulation, wound healing, and metabolic effects via intranasal delivery.
Also nootropic
A cyclic heptapeptide melanocortin receptor agonist and active metabolite of Melanotan II. Unlike peripheral vasodilators, PT-141 acts centrally via the CNS to modulate arousal and food intake pathways.
Also nootropic
A potent cyclic analog of α-MSH that activates melanocortin receptors broadly. Studied for UV-independent melanogenesis, appetite suppression, and as the parent compound of PT-141 (Bremelanotide).